Abstract
A phase II study of the synthetic polyelectrolyte Carbetimer 6500 mg/m2 IV daily for five days every 21-day cycle was conducted in patients with metastatic melanoma. No responses were seen in 18 evaluable patients. Two patients had stable disease for five months. Toxicity was generally manageable and included mild hyperphosphatemia, mild proteinuria, fatigue, pain at the injection site, and nausea. Carbetimer is inactive in metastatic melanoma at this dose and schedule.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Grin-Jorgenson CM, Rigel DS, Friedman RJ: The worldwide incidence of malignant melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S (eds) Cutaneous Melanoma. Lippincott, Philadelphia, 1992, pp 28–45
Kish JA, Kopecky K, Samson MK, Von Hoff DD, Fletcher WS, Kempf RA, Muggia FM: Evaluation of fludarabine phosphate in malignant melanoma. A Southwest Oncology Group Study. Invest N Drugs 9:105–108, 1991
Cohen SM, Ohnuma T, Cheung T, Holland JF: Bleomycin, carmustine, vincristine, and dacarbazine in patients with metastatic melanoma. Cancer Treat Rep 67:947–948, 1983
Luikart SK, Kennealey GT, Kirkwood JM: Randomized phase II trial of vinblastine, bleomycin, and cisdichlorodiammineplatinum versus dacarbazine in malignant melanoma. J Clin Oncol 2:164, 1984
Mitchell MS, Harel W, Kempf RA, Hu E, Kan-Mitchell J, Boswell WD, Dean G, Stevenson L: Active-specific immunotherapy for melanoma. J Clin Oncol 8:856–869, 1990
Dutcher JP, Creekmore S, Weiss GR, Margolin K, Markowitz AB, Roper M, Parkinson D, Ciobanu N, Fisher RI, Boldt DH, Doroshow JH, Rayner AA, Hawkins M, Atkins M: A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 7:477–485, 1989
Fields JE, Ascuali SS, Johnson JH, Johnson RK: Carboxyimamidate, a low-molecular-weight polyelectrolyte with antitumor properties and low toxicity. J Med Chem 25:1060–1064, 1982
Ardalan B, Paget GE: Mechanism of action of a new antitumor agent, carbetimer. Cancer Res 46:5473–5476, 1986
Grunberg SM, Ehler E, Francis RB Jr, Mitchell MS: Phase I trial of a 5-day course of carbetimer. Invest N Drugs 8:S41-S49, 1990
Dodion P, De Valeriola D, Body JJ, Houa M, Noel P, Abrams J, Crespeigne N, Wery F, Kenis Y: Phase I clinical trial with carbetimer. Eur J Clin Oncol 25:279–286, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Quan, W.D.Y., Mitchell, M.S. Phase II trial of carbetimer in metastatic melanoma. Invest New Drugs 11, 231–233 (1993). https://doi.org/10.1007/BF00874162
Issue Date:
DOI: https://doi.org/10.1007/BF00874162